UBS Raises Price target on Acadia Healthcare (ACHC) Following Announced Priory Group Acquisition

Acadia Healthcare (ACHC): Jefferies Top Pick for 2016

Jefferies analyst, Brian Tanquilut, highlighted Acadia Healthcare (NASDAQ: ACHC), as his top pick on Medicaid potential as coverage expands to Mental Health. No change to the Buy rating or $100 PT.

The thesis on ACHC is organic growth through consistent bed additions (as patient demand remains strong).... More

Acadia Healthcare (ACHC) Prices 10M Shares at $61

Acadia Healthcare Company, Inc. (NASDAQ: ACHC) announced the pricing of its previously announced underwritten public offering of 10,000,000 shares of common stock at a public offering price of $61.00 per share, for gross proceeds to the Company of $610 million, before the underwriting discount and offering... More

Pre-Open Stock Movers 01/06: (CNAT) (CCXI) (MBLY) Higher; (CMG) (VRX) (AAPL) Lower (more...)

Conatus Pharmaceuticals (NASDAQ: CNAT) 24.6% HIGHER; three-month, double-blind, placebo-controlled stage of the companys multicenter Phase 2 Liver Cirrhosis clinical trial showed a statistically significant reduction in caspase-cleaved cytokeratin 18 (cCK18) vs. placebo (p=0.04) in the overall patient population when adjusted for differences between treatment and placebo groups in baseline Model for End-stage Liver Disease (MELD)1 score and disease etiology as specified in the trial statistical analysis plan.

ChemoCentryx, Inc., (Nasdaq: CCXI) 23.9%... More

After-Hours Stock Movers 01/05: (CNAT) (ICON) (BLUE) Higher; (EPZM) (CEMP) (OTIC) Lower (more...)

Conatus Pharmaceuticals (NASDAQ: CNAT) 15% HIGHER; three-month, double-blind, placebo-controlled stage of the companys multicenter Phase 2 Liver Cirrhosis clinical trial showed a statistically significant reduction in caspase-cleaved cytokeratin 18 (cCK18) vs. placebo (p=0.04) in the overall patient population when adjusted for differences between treatment and placebo groups in baseline Model for End-stage Liver Disease (MELD)1 score and disease etiology as specified in the trial statistical analysis plan.

Epizyme, Inc. (NASDAQ: EPZM) 10% LOWER; announced that it intends to... More

Acadia Healthcare (ACHC) Announces 10M Share Common Stock Offering

Acadia Healthcare Company, Inc. (NASDAQ: ACHC) (Acadia or the Company) today announced a proposed underwritten public offering of 10,000,000 shares of its common stock.

Acadia intends to use the proceeds from the offering principally to fund its acquisition strategy, particularly to fund a portion of the purchase price for its planned acquisition of the Priory Group, a leading provider of behavioral healthcare services in the United Kingdom,... More